Abstract
Objective
The association of insulin glargine with overall and site-specific cancer risk remains uncertain. This study aims to provide relevant evidence from mainland China.
Methods
Based on the Shanghai Link Healthcare Database, patients newly treated with insulin glargine or neutral protamine Hagedorn (NPH) insulin between January 1, 2013 and December 31, 2020 were identified and followed up until December 31, 2021. In addition to the original cohort, we created a 1:1 propensity score-matched cohort with balanced baseline characteristics. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident cancers, comparing insulin glargine with NPH insulin.
Results
A total of 26,810 insulin glargine users and 47,765 NPH insulin users were enrolled in the final analysis. During a median follow-up of 4.18 years, 3903 patients developed cancer. Including a 1-year lag period, insulin glargine use was not associated with increased cancer risk compared to NPH insulin use in both the original cohort (HR 1.02, 95% CI 0.95–1.10) and the propensity score-matched cohort (HR 1.01, 95% CI 0.94–1.09). In stratified analyses by sex, age, and cancer site, as well as in sensitivity analyses at different lag periods, the estimated cancer risk, although fluctuating, remained uncorrelated without any substantial change.
Conclusion
Insulin glargine is not associated with the risk of overall and site-specific cancers compared to NPH insulin among patients with type 2 diabetes mellitus.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
References
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–21. https://doi.org/10.3322/caac.20078.
Qi J, He P, Yao H, Song R, Ma C, Cao M, Cui B, Ning G. Cancer risk among patients with type 2 diabetes: a real-world study in Shanghai, China. J Diabetes. 2019;11:878–83. https://doi.org/10.1111/1753-0407.12926.
Hemkens L, Grouven U, Bender R, Günster C, Gutschmidt S, Selke G, Sawicki P. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44. https://doi.org/10.1007/s00125-009-1418-4.
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54. https://doi.org/10.1007/s00125-009-1444-2.
Colhoun H. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755–65. https://doi.org/10.1007/s00125-009-1453-1.
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77. https://doi.org/10.1007/s00125-009-1440-6.
Ljung R, Talbäck M, Haglund B, Jonasson J, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a three-year population-based observation. Acta oncologica (Stockholm, Sweden). 2011;50:685–93. https://doi.org/10.3109/0284186x.2011.558913.
Morden N, Liu S, Smith J, Mackenzie T, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 2011;34:1965–71. https://doi.org/10.2337/dc11-0699.
Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS. Cancer risk associated with insulin glargine among adult type 2 diabetes patients–a nationwide cohort study. PLoS One. 2011;6:e21368. https://doi.org/10.1371/journal.pone.0021368.
Buchs AE, Silverman BG. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism. 2011;60:1379–85. https://doi.org/10.1016/j.metabol.2011.05.002.
Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011;54:2254–62. https://doi.org/10.1007/s00125-011-2190-9.
Ruiter R, Visser L, van Herk-Sukel M, Coebergh J, Haak H, Geelhoed-Duijvestijn P, Straus S, Herings R, Stricker B. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55:51–62. https://doi.org/10.1007/s00125-011-2312-4.
Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard M, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012;55:644–53. https://doi.org/10.1007/s00125-011-2429-5.
Kostev K. Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin. Diabetologia. 2012;55:1554–5. https://doi.org/10.1007/s00125-012-2497-1.
Lind M, Fahlen M, Eliasson B, Oden A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes. 2012;6:53–9. https://doi.org/10.1016/j.pcd.2011.10.004.
Ljung R, Talbäck M, Haglund B, Jonasson J, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of breast cancer-a four-year population-based observation. Acta oncologica (Stockholm, Sweden). 2012;51:400–2. https://doi.org/10.3109/0284186x.2011.624118.
van Staa T, Patel D, Gallagher A, de Bruin M. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia. 2012;55:654–65. https://doi.org/10.1007/s00125-011-2390-3.
Fagot J, Blotière P, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: a French nationwide cohort study based on national administrative databases. Diabetes Care. 2013;36:294–301. https://doi.org/10.2337/dc12-0506.
Stürmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, Macdonald E, Wang R, Lavange LM, Pate V, Buse JB. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care. 2013;36:3517–25. https://doi.org/10.2337/dc13-0263.
Lim S, Stember K, He W, Bianca P, Yelibi C, Marquis A, Stürmer T, Buse J, Meigs J. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. PloS one. 2014;9:e109433. https://doi.org/10.1371/journal.pone.0109433.
Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, Ferrara A. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013;36:3953–60. https://doi.org/10.2337/dc13-0140.
Peeters PJ, Bazelier MT, Leufkens HG, Auvinen A, van Staa TP, de Vries F, De Bruin ML. Insulin glargine use and breast cancer risk: associations with cumulative exposure. Acta Oncol. 2016;55:851–8. https://doi.org/10.3109/0284186x.2016.1155736.
Wu J, Azoulay L, Majdan A, Boivin J, Pollak M, Suissa S. Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes. J Clin Oncol. 2017;35:3647–53. https://doi.org/10.1200/jco.2017.73.4491.
But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A, Starup-Linde J, Schmidt MK, Furu K, de Vries F, Karlstad O, Ekstrom N, Haukka J. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia. 2017;60:1691–703. https://doi.org/10.1007/s00125-017-4312-5.
Pradhan R, Yin H, Yu O, Azoulay L. The use of long-acting insulin analogs and the risk of colorectal cancer among patients with type 2 diabetes: a population-based cohort study. Drug Saf. 2020;43:103–10. https://doi.org/10.1007/s40264-019-00892-5.
Simó R, Plana-Ripoll O, Puente D, Morros R, Mundet X, Vilca L, Hernández C, Fuentes I, Procupet A, Tabernero J, Violán C. Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PloS one. 2013;8:e79968. https://doi.org/10.1371/journal.pone.0079968.
Grimaldi-Bensouda L, Cameron D, Marty M, Barnett A, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin J, Khachatryan A, Rossignol M, Bénichou J, Alpérovitch A, Abenhaim L. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care. 2014;37:134–43. https://doi.org/10.2337/dc13-0695.
Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella C. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010;33:1997–2003. https://doi.org/10.2337/dc10-0476.
Wu J, Filion K, Azoulay L, Doll M, Suissa S. Effect of long-acting insulin analogs on the risk of cancer: a systematic review of observational studies. Diabetes Care. 2016;39:486–94. https://doi.org/10.2337/dc15-1816.
Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009;374:511–3. https://doi.org/10.1016/s0140-6736(09)61307-6.
Tamim H, Monfared A, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidem Dr S. 2007;16:250–8. https://doi.org/10.1002/pds.1360.
Johnson J, Bowker S, Richardson K, Marra C. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. https://doi.org/10.1007/s00125-011-2242-1.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79. https://doi.org/10.1002/sim.6607.
Rosenstock J, Fonseca V, McGill J, Riddle M, Hallé J, Hramiak I, Johnston P, Davis M. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009;52:1971–3. https://doi.org/10.1007/s00125-009-1452-2.
Home P, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52:2499–506. https://doi.org/10.1007/s00125-009-1530-5.
Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28. https://doi.org/10.1056/NEJMoa1203858.
Bordeleau L, Yakubovich N, Dagenais G, Rosenstock J, Probstfield J, Chang YuP, Ryden L, Pirags V, Spinas G, Birkeland K, Ratner R, Marin-Neto J, Keltai M, Riddle M, Bosch J, Yusuf S, Gerstein H. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care. 2014;37:1360–6. https://doi.org/10.2337/dc13-1468.
Sciacca L, Vella V, Frittitta L, Tumminia A, Manzella L, Squatrito S, Belfiore A, Vigneri R. Long-acting insulin analogs and cancer. Nutr Metab Cardiovasc Dis. 2018;28:436–43. https://doi.org/10.1016/j.numecd.2018.02.010.
Vigneri R, Sciacca L, Vigneri P. Rethinking the relationship between insulin and cancer. Trends Endocrinol Metab. 2020;31:551–60. https://doi.org/10.1016/j.tem.2020.05.004.
Ter Braak B, Siezen C, Kannegieter N, Koedoot E, van de Water B, van der Laan J. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. Arch Toxicol. 2014;88:953–66. https://doi.org/10.1007/s00204-014-1201-2.
Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999–1005. https://doi.org/10.2337/diabetes.49.6.999.
Gallagher E, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia. 2016;59:2018–25. https://doi.org/10.1007/s00125-016-4000-x.
Yoshida K, Solomon D, Kim S. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11:437–41. https://doi.org/10.1038/nrrheum.2015.30.
Acknowledgments
The authors thank all the researchers involved in this study for their valuable contributions.
Funding
This study was funded by the National Key R&D Program of China (no. 2018YFC1314802).
Author information
Authors and Affiliations
Contributions
Jiying Qi: formal analysis, investigation, writing—original draft. Ping He: data curation, resources. Huayan Yao: data curation, software. Wen Sun: data curation, software. Zizheng Zhang: formal analysis. Bin Cui: conceptualization, funding acquisition, methodology, writing—original draft, writing—review and editing. Guang Ning: conceptualization, project administration, supervision, writing—review and editing.
Corresponding authors
Ethics declarations
Ethics approval
This study was approved by the Ethics Committee of Ruijin Hospital (2020-226Y).
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Qi, J., He, P., Yao, H. et al. Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China. Int J Diabetes Dev Ctries 44, 137–144 (2024). https://doi.org/10.1007/s13410-023-01230-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13410-023-01230-3